Featured Research

from universities, journals, and other organizations

Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years

Date:
January 25, 2012
Source:
JAMA and Archives Journals
Summary:
Among women with invasive epithelial ovarian cancer, patients having a germline (gene change in a reproductive cell that could be passed to offspring) mutation in the BRCA1 or BRCA2 genes was associated with improved five-year overall survival, with BRCA2 carriers having the best prognosis, according to a new study.

Among women with invasive epithelial ovarian cancer, patients having a germline (gene change in a reproductive cell that could be passed to offspring) mutation in the BRCA1 or BRCA2 genes was associated with improved 5-year overall survival, with BRCA2 carriers having the best prognosis, according to a study in the January 25 issue of JAMA.

Related Articles


"Germline mutations in the tumor suppressor genes BRCA1 and BRCA2 are the strongest known genetic risk factors for both breast and epithelial ovarian cancer (EOC) and are found in 6 percent to 15 percent of women with EOC," according to background information in the article. "The relative prognosis of BRCA1/2 carriers and noncarriers is unclear."

Kelly L. Bolton, Ph.D., of the National Cancer Institute, Bethesda, Md., and colleagues conducted a study to provide evidence of the relative effect of germline BRCA1 and BRCA2 mutations on prognosis for women with epithelial ovarian cancer. The study consisted of a pooled analysis of 26 observational studies on the survival of women with ovarian cancer, which included data from 1,213 EOC cases with pathogenic germline mutations in BRCA1 (n = 909) or BRCA2 (n = 304) and from 2,666 noncarriers recruited and followed up at variable times between 1987 and 2010. During the 5 years following EOC diagnosis, 1,766 deaths occurred.

The researchers found that 5-year overall survival was 36 percent for noncarriers of the gene mutations, 44 percent for BRCA1 carriers, and 52 percent for BRCA2 carriers. In a model only adjusted for study site and year of diagnosis, BRCA1 carriers had a more favorable survival than noncarriers, which improved slightly after additional adjustment for stage, grade, histology, and age at diagnosis. BRCA2 carriers had a greater survival advantage compared with noncarriers, particularly after adjusting for other prognostic factors.

The survival advantage for BRCA1 and BRCA2 carriers compared with noncarriers was present but less marked among women who reported a family history of ovarian, breast cancer, or both.

"Our study results have potentially important implications for the clinical management of patients with EOC. Most immediately, our findings can be used by health care professionals for patient counseling regarding expected survival. BRCA1 and BRCA2 carriers with EOC respond better than noncarriers to platinum-based chemotherapies and have improved survival despite the fact that the disease is generally diagnosed at a later stage and higher grade. If patients could be stratified based on their BRCA status, their treatment could be tailored to reflect this, with noncarriers targeted for more aggressive treatments. Our data provide further support that there may be different functional mechanisms involved in the etiology of different subtypes of EOCs and, therefore, different therapeutic targets based on germline and somatic [changes to the genetics of a multicellular organism which are not passed on to its offspring through the germline] genetic variation," the researchers write.

." .. given the important prognostic information provided by BRCAl and BRCA2 status and the potential for personalized treatment in carriers, the routine testing of women presenting with high-grade serous EOC may now be warranted."

Editorial: Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer

David M. Hyman, M.D., and David R. Spriggs, M.D., of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, write in an accompanying editorial that the data from this study have important implications for the future of ovarian cancer research and treatment.

"Phase 3 studies that do not stratify by BRCA mutation status or account for this factor in a preplanned statistical analysis risk possible confounding because approximately 15 percent of unselected patients with serous ovarian cancer will carry germline BRCAl/2 mutations. Moreover, other studies have found differences in chemotherapy responsiveness and progression-free survival between sporadic BRCAl -and BRCA2-associated ovarian cancers. Germline BRCA testing needs to be consistently incorporated into both the routine management and future phase 3 trials of ovarian cancer."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. K. L. Bolton, G. Chenevix- Trench, C. Goh, S. Sadetzki, S. J. Ramus, B. Y. Karlan, D. Lambrechts, E. Despierre, D. Barrowdale, L. McGuffog, S. Healey, D. F. Easton, O. Sinilnikova, J. Benitez, M. J. Garcia, S. Neuhausen, M. H. Gail, P. Hartge, S. Peock, D. Frost, D. G. Evans, R. Eeles, A. K. Godwin, M. B. Daly, A. Kwong, E. S. K. Ma, C. Lazaro, I. Blanco, M. Montagna, E. D'Andrea, M. O. Nicoletto, S. E. Johnatty, S. K. Kjaer, A. Jensen, E. Hogdall, E. L. Goode, B. L. Fridley, J. T. Loud, M. H. Greene, P. L. Mai, A. Chetrit, F. Lubin, G. Hirsh-Yechezkel, G. Glendon, I. L. Andrulis, A. E. Toland, L. Senter, M. E. Gore, C. Gourley, C. O. Michie, H. Song, J. Tyrer, A. S. Whittemore, V. McGuire, W. Sieh, U. Kristoffersson, H. Olsson, A. Borg, D. A. Levine, L. Steele, M. S. Beattie, S. Chan, R. L. Nussbaum, K. B. Moysich, J. Gross, I. Cass, C. Walsh, A. J. Li, R. Leuchter, O. Gordon, M. Garcia-Closas, S. A. Gayther, S. J. Chanock, A. C. Antoniou, P. D. P. Pharoah. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA: The Journal of the American Medical Association, 2012; 307 (4): 382 DOI: 10.1001/jama.2012.20
  2. D. M. Hyman, D. R. Spriggs. Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer. JAMA: The Journal of the American Medical Association, 2012; 307 (4): 408 DOI: 10.1001/jama.2012.24

Cite This Page:

JAMA and Archives Journals. "Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years." ScienceDaily. ScienceDaily, 25 January 2012. <www.sciencedaily.com/releases/2012/01/120124162343.htm>.
JAMA and Archives Journals. (2012, January 25). Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2012/01/120124162343.htm
JAMA and Archives Journals. "Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years." ScienceDaily. www.sciencedaily.com/releases/2012/01/120124162343.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) — Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins